Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of Thalidomide, Bendamustine and Dexamethasone (BTD) Versus Bortezomib, Bendamustine and Dexamethasone (BBD) in Patients With Renal Failure Defined as a GFR Below 30 Mls/Min

NCT02424851 is registered in ClinicalTrials.gov with Oxford University Hospitals NHS Trust as lead sponsor.

NCT NCT02424851
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02424851 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of Thalidomide, Bendamustine and Dexamethasone (BTD) Versus Bortezomib, Bendamustine and Dexamethasone (BBD) in Patients With Renal Failure Defined as a GFR Below 30 Mls/Min
Lead sponsor
Oxford University Hospitals NHS Trust
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2014
Completion date
April 20, 2020
Enrollment
31 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease, multiple myeloma